Arkolith/Insider Trading/ASND/Form 4

Smith Scott Thomas

EVP & Chief Financial OfficerAscendis Pharma A/S (ASND) · full profile →Form 4 · filed Jun 2, 2026
Net Buying
Open-Market Buys
$22K
Open-Market Sells
$0
Net Open-Market Flow
$22K
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jun 2, 2026Buy(P)100$219.00$22K4K

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001610717-26-000179) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML